Cosciens Biopharma Inc (CSCI.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 289 | 287 | 287 | 325 | 392 |
| Income taxes - deferred | 10 | 0 | 0 | 0 | 1,077 |
| Accounts receivable | N/A | 1,709 | -607 | 1,343 | N/A |
| Other Working Capital | 439 | 951 | -2,425 | 1,327 | 754 |
| Other Operating Activity | -2,208 | -3,623 | -1,702 | -4,875 | -5,222 |
| Operating Cash Flow | $-1,470 | $-676 | $-4,447 | $-1,880 | $-2,999 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 193 | 4 | -48 | -611 | -309 |
| Other Investing Activity | 8 | 0 | 0 | -4 | -7 |
| Investing Cash Flow | $201 | $4 | $-48 | $-615 | $-316 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -15 | -85 | -65 | -200 | -109 |
| Other Financing Activity | 0 | 0 | -42 | 0 | -93 |
| Financing Cash Flow | $-15 | $-85 | $-107 | $-200 | $-202 |
| Exchange Rate Effect | 67 | -52 | 177 | 60 | -88 |
| Beginning Cash Position | 8,524 | 9,333 | 13,758 | 16,393 | 19,998 |
| End Cash Position | 7,307 | 8,524 | 9,333 | 13,758 | 16,393 |
| Net Cash Flow | $-1,284 | $-757 | $-4,602 | $-2,695 | $-3,517 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,470 | -676 | -4,447 | -1,880 | -2,999 |
| Capital Expenditure | -46 | N/A | -49 | -615 | -309 |
| Free Cash Flow | -1,516 | -676 | -4,496 | -2,495 | -3,308 |